Cristina Molina-Martinez
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Factors associated with the effectiveness and safety of Janus kinase inhibitors in rheumatoid arthritis: an 8-year observational study from the JAGUAR Registry.
Journal: RMD open
Published: April 21, 2026
Etrasimod: Modulating Sphingosine-1-Phosphate Receptors to Treat Ulcerative Colitis.
Journal: Journal of clinical medicine
Published: March 30, 2025
Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment.
Journal: Frontiers in medicine
Published: October 16, 2024
Are There Sex-Related Differences in the Effectiveness of Janus Kinase Inhibitors in Rheumatoid Arthritis Patients?
Journal: Journal of clinical medicine
Published: March 17, 2024
Adverse reactions to Janus kinase inhibitors: Study of their incidence and predictive factors in patients with rheumatoid arthritis
Journal: Medicina clinica
Published: January 20, 2024
Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis.
Journal: Medicina (Kaunas, Lithuania)
Published: January 18, 2024
Patient-related factors influencing the effectiveness and safety of Janus Kinase inhibitors in rheumatoid arthritis: a real-world study.
Journal: Scientific reports
Published: October 13, 2023
Are all JAK inhibitors for the treatment of rheumatoid arthritis equivalent? An adjusted indirect comparison of the efficacy of tofacitinib, baricitinib, upadacitinib, and filgotinib.
Journal: Clinical rheumatology
Published: June 28, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026